TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study

Phase 3

Completed

• Conditions: Chronic Myeloid Leukemia
• Interventions: Drug: Peginterferon α2b; Drug: Nilotinib

• Registration Number: NCT01657604
• Lead Sponsor: University of Jena

Brief Summary

Advances in Chronic Myeloid Leukemia (CML) therapy led to an expected survival prolongation of \> 20 years after diagnosis. So far, discontinuation of tyrosine kinase inhibitors led to recurrence of disease in the majority of patients. The trial aims to improve treatment strategies in CML by improving induction therapy and deescalating maintenance therapy using low dose IFN as inducer of immunosurveillance. The trial will provide important data on the duration of active therapy in CML patients. Considering the rapidly increasing prevalence of CML this is of individual but also socioeconomic importance.

Detailed Description

Objectives

Primary:

* Evaluation of the major molecular response (MMR) rate at 18 months of nilotinib compared to nilotinib+pegylated Interferon alpha (IFN) in adult patients with newly diagnosed Ph/BCR-ABL CML in chronic phase.

* Evaluation of the feasibility to discontinue drug therapy in stable deep molecular response (MR4) after nilotinib versus IFN maintenance therapy.

Secondary:

* Evaluation of the efficacy and tolerability of IFN added to nilotinib 2x300 mg/day.

* Evaluation of the efficacy and tolerability of a maintenance therapy with nilotinib versus IFN after stable MMR after at least 24 months of nilotinib therapy.

Study Timeline

• Study First Submitted: 2012-07-09
• Study First Submitted QC: 2012-08-03
• Study First Posted: 2012-08-06
• Study Start: 2012-08-24
• Primary Completion: 2022-05-31
• Study Completion: 2022-05-31
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-09
• Last Update Posted: 2023-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 717

Inclusion Criteria

• Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph chromosome [t(9;22)(q34;q11)]
• Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR (Cross, et al 1994) are eligible as well
• ECOG performance status of < 2
• Pretreatment with hydroxyurea for 6 months and imatinib or nilotinib for a duration of up to 6 weeks is permitted
• Age ≥ 18 years old (no upper age limit given)
• Normal serum levels ≥ LLN (lower limit of normal) of potassium, magnesium, total calcium corrected for serum albumin, or corrected to within normal limits with supplements
• ASAT and ALAT ≤ 2.5 x ULN (upper limit of normal) or ≤ 5.0 x ULN if considered due to leukemia
• Alkaline phosphatase ≤ 2.5 x ULN unless considered due to leukemia
• Total bilirubin ≤ 1.5 x ULN, except known Mb. Gilbert
• Serum lipase and amylase ≤ 1.5 x ULN
• Serum creatinine ≤ 2 x ULN
• Written informed consent prior to any study procedures being performed

Exclusion Criteria

• Known impaired cardiac function, including any of the following:

  • Left ventricular ejection fraction (LVEF) < 45%
  • Congenital long QT syndrome
  • History of or presence of clinically significant ventricular or atrial tachyarrhythmias

• Clinically significant resting bradycardia (< 50 beats per minute)

• QTc > 450 msec on screening ECG. If QTc > 450 ms and electrolytes are not within normal ranges before nilotinib dosing, electrolytes should be corrected and then the patient rescreened for QTc criterion

• Myocardial infarction within 12 months prior to starting therapy

• Other clinical significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension)

• History of acute (i.e., within 1 year of starting study medication) or chronic pancreatitis

• Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores > 6), even if controlled

• Other concurrent uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol

• Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery)

• Concomitant medications with potential QT prolongation

• Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4

• Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy

• Patients who are pregnant or breast feeding, or women of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to administration of nilotinib). Post menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug

• Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)

• Active autoimmune disorder, including autoimmune hepatitis

• Known serious hypersensitivity reactions to peginterferon alfa-2b or interferon alfa-2b or drug excipients

• Known serious hypersensitivity reactions to nilotinib

• Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention

• Patients unwilling or unable to comply with the protocol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nilotinib+IFN	Peginterferon α2b	Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
Nilotinib	Nilotinib	Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.

Primary Outcome Measures

Name	Time	Method
MMR rate at 18 months of nilotinib monotherapy versus nilotinib+pegylated interferon alpha	at least 18 months after start of study treatment	rate of MMR 18 months after randomization for each study treatment
rate of continuous MMR after discontinuation of nilotinib versus pegylated interferon alpha	at least 12 months after stopping all therapy	rate of patients with molecular relapse (loss of MMR) 12 months after discontinuation of any treatment for CML

Secondary Outcome Measures

Name	Time	Method
rate of MR4 and MR4.5 during maintenance therapy and after discontinuation	start of maintenance therapy (after at least 24 months of treatment) until end of study duration (at least 36 months)
rate of CCyR and MMR	at 12, 18 and 24 months after start of treatment
Time to CCyR, MMR, MR4 and MR4.5	date of randomization until time to endpoints or end of study duration (at least 36 months)	this time to-event endpoints give an impression of the velocity of drug response and of the time until a certain remission should be waited for
Progression-Free Survival (PFS)	at 12, 24 and 60 months after start of treatment
Rate of patients off treatment for at least 6 months	at 60 months after start of treatment	all patients and comparison of treatment arms
safety and tolerability profile of nilotinib in comparison with nilotinib+pegylated interferon alpha and pegylated interferon alpha	time of first study treatment until 28 days after stop of study treatment (expected 36 months)	the time of risk is the time while receiving the therapy plus 28 days thereafter
patients compliance to nilotinib based therapies	until stop of study treatment (at least 36 months)
quality of life during induction therapy with ilotinib versus nilotinib+pegylated interferon alpha and during maintenance therapy with nilotinib versus pegylated interferon alpha	during induction therapy (until at least 24 months), during maintenance therapy (until at least 36 months)
pharmacoeconomics of the treatment strategies	after end of study (expected in December 2020) (up to 8 years)
Overall Survival (OS)	at 12, 24 and 60 months after start of treatment

Trial Locations

Locations (111)

University Hospital and Masaryk University Brno; 🇨🇿 Brno, Czechia

Universitätsklinikum Aachen Medizinische Klinik IV; 🇩🇪 Aachen, Germany

Gesundheitszentrum St. Marien GmbH, Onkologie/ Hämatologie Onkologisches Zentrum; 🇩🇪 Amberg, Germany

MVZ am Klinikum Arnsberg GmbH, Hämatologie - Internistische Onkologie; 🇩🇪 Arnsberg, Germany

Studienzentrum Drs. Klausmann; 🇩🇪 Aschaffenburg, Germany

Klinikum Augsburg; 🇩🇪 Augsburg, Germany

Klinikum Bayreuth GmbH; 🇩🇪 Bayreuth, Germany

Vivantes Netzwerk für Gesundheit GmbH, Klinikum Neukölln, Klinik für Innere Medizin - Hämatologie und Onkologie; 🇩🇪 Berlin, Germany

Charité CVK, CC14, Klinik für Hämatologie und Onkologie; 🇩🇪 Berlin, Germany

Evangelisches Klinikum Bethel; 🇩🇪 Bielefeld, Germany

Scroll for more (101 remaining)